BSX
Boston ScientificNYSEHealth CareMedical DevicesSnapshot 2026-05-08
As of May 8, 2026, BSX has a composite score of 13.1 and a signal label of "mild favorable." This score is influenced by a medium confidence level of 76.0 and elevated market risk at 58.7. Key drivers include macroeconomic factors such as labor, rates, growth, and inflation, with recent guidance changes impacting the outlook. The assessment is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.25
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $0.86 → $0.83 (-3.7% / 30d). 0 raised, 21 cut, 25 covering analysts.
0 upgrades, 0 downgrades / 30d, 15 maintained. 94% of analysts rate Buy.
14 PT revisions / 30d. Avg target 31.5% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
10 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Drive net sales growthgrowthbehind5% progress
4/22: “The company estimates net sales growth for the full year 2026 to be approximately 7.0 to 8.5 percent.”
Why this status
Stated in 2 of last 2 quarters. Net sales grew from $4,663 million in 2025-Q1 to $5,203 million in 2026-Q1, a 11.6% increase. The company is delivering on its growth target, with guidance for 2026 set at 7.0 to 8.5 percent growth.
- 2.Expand cardiovascular segmentproductmixed33% progress
4/22: “Achieved 13.5 percent reported growth in the cardiovascular segment.”
Why this status
Stated in 2 of last 2 quarters. Cardiovascular segment revenue grew from $3,085 million in 2025-Q1 to $3,503 million in 2026-Q1, a 13.5% increase. The company is delivering on its focus to expand this segment through innovation and market expansion.
- 3.Enhance operational efficiencycostmixed61% progress
4/22: “Our global team and the strength of our category leadership strategy enabled us to deliver solid results.”
Why this status
Stated in 2 of last 2 quarters. While specific cost metrics are not detailed, management emphasizes operational efficiency as a driver of solid results. The focus remains on leveraging category leadership to support growth and profitability, though specific efficiency gains are not quantified.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 51%; 252d 33%.
Drawdown — Max 1y −50%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.39 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 45/100, drawdown 0/100, beta 39/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Drive net sales growth
GrowthFocus on achieving net sales growth of 7.0 to 8.5 percent for 2026.
BehindStated in 2 of last 2 quarters. Net sales grew from $4,663 million in 2025-Q1 to $5,203 million in 2026-Q1, a 11.6% increase. The company is delivering on its growth target, with guidance for 2026 set at 7.0 to 8.5 percent growth.
5%CEO/CFO:“The company estimates net sales growth for the full year 2026 to be approximately 7.0 to 8.5 percent.”Multiple sourcesSource dated 2026-04-22Stated 2 of last 8 quartersFirst seen 2026-04-22Show history (2)
- 2026-Q1Press release
“Reported net sales of $5.203 billion, representing an increase of 11.6 percent.”
- 2025-Q4Press release
“Generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent.”
- #2
Expand cardiovascular segment
ProductAchieve significant growth in the cardiovascular segment, focusing on innovation and market expansion.
MixedStated in 2 of last 2 quarters. Cardiovascular segment revenue grew from $3,085 million in 2025-Q1 to $3,503 million in 2026-Q1, a 13.5% increase. The company is delivering on its focus to expand this segment through innovation and market expansion.
33%CEO/CFO:“Achieved 13.5 percent reported growth in the cardiovascular segment.”Press releaseSource dated 2026-04-22Stated 2 of last 8 quartersFirst seen 2026-04-22Show history (2)
- 2026-Q1Press release
“Achieved 13.5 percent reported growth in the cardiovascular segment.”
- 2025-Q4Press release
“Cardiovascular: 18.2 percent reported growth.”
- #3
Enhance operational efficiency
CostFocus on improving operational efficiency to support growth and profitability.
MixedStated in 2 of last 2 quarters. While specific cost metrics are not detailed, management emphasizes operational efficiency as a driver of solid results. The focus remains on leveraging category leadership to support growth and profitability, though specific efficiency gains are not quantified.
61%CEO/CFO:“Our global team and the strength of our category leadership strategy enabled us to deliver solid results.”Press releaseSource dated 2026-04-22Stated 2 of last 8 quartersFirst seen 2026-04-22Show history (2)
- 2026-Q1Press release
“Our global team and the strength of our category leadership strategy enabled us to deliver solid results.”
- 2025-Q4Press release
“2025 was another exceptional year for Boston Scientific, with our global teams delivering differentiated innovation and high performance.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
59 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
BSX Boston Scientific | +13 | fair | elevated |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2026-04-22)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2026-04-22)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2216d agoItem 2.02
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
earnings preannouncementneutralscore 45 - 2026-02-262mo agoItem 1.01
Entry into a Material Definitive Agreement. Revolving Credit Agreement On February 26, 2026, Boston Scientific Corporation (the “ Company ”) entered into a $3.000 billion revolving credit agreement (the “ 2026 Revolving Credit Agreement ”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent. The Company may borrow from time to time up to $3,000,000,000 in revolving credit loans under the 2026 Revolving C…
capital allocationneutralscore 13 - 2026-02-232mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director…
executive changeneutralscore 10 - 2026-02-262mo agoItem 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. With respect to the 2026 Credit Agreements, the information set forth above under
capital allocationnegativescore 10 - 2026-02-262mo agoItem 1.02
Termination of a Material Definitive Agreement. In connection with the entry into the 2026 Revolving Credit Agreement, on February 26, 2026, the Company terminated a prior revolving credit agreement, dated as of May 10, 2021, as amended by that certain Amendment to the Credit Agreement dated as of December 21, 2022, the Second Amendment to the Credit Agreement, dated as of March 1, 2023, and the Third Amendment to the Credit Agreement, dated as of May 10, 2024, by and among the Company, as bo…
mna activitynegativescore 10
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.